방광암 시장(2026-2030년)

The global bladder cancer market is forecasted to grow by USD 4677.5 mn during 2025-2030, accelerating at a CAGR of 15.0% during the forecast period. The report on the global bladder cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing burden of bladder cancer diagnosis across aging populations, expanding adoption of immunotherapy and targeted treatment approaches, increasing investment in oncology research and clinical development programs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global bladder cancer market is segmented as below:

By Disease Type

• Transitional cell carcinoma
• Squamous cell carcinoma
• Adenocarcinoma
• Others

By Drug Class

• Immunotherapy drugs
• Chemotherapy drugs
• Target therapy drugs

By End-User

• Hospitals
• Specialty clinics
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the growing shift toward non invasive diagnostic and monitoring solutions as one of the prime reasons driving the global bladder cancer market growth during the next few years. Also, growing shift toward bladder preservation treatment strategies and expanding collaboration ecosystem across pharmaceutical, biotechnology, and academic organizations will lead to sizable demand in the market.

The report on the global bladder cancer market covers the following areas:

• Global bladder cancer market sizing
• Global bladder cancer market forecast
• Global bladder cancer market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global bladder cancer market vendors that include Adaptimmune Therapeutics plc, Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Ferring BV, G1 Therapeutics Inc., Incyte Corp., Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., Photocure ASA, UroGen Pharma Ltd. Also, the global bladder cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Disease Type
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Bladder Cancer Market 2020 - 2024
  • Historic Market Size - Data Table on Global Bladder Cancer Market 2020 - 2024 ($ million)
• 5.2 Disease Type segment analysis 2020 - 2024
  • Historic Market Size - Disease Type Segment 2020 - 2024 ($ million)
• 5.3 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.4 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global bladder cancer market
• 6.2 Impact of geopolitical conflicts on global bladder cancer market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Disease Type

• 8.1 Market segments
• 8.2 Comparison by Disease Type
• 8.3 Transitional cell carcinoma - Market size and forecast 2025-2030
• 8.4 Squamous cell carcinoma - Market size and forecast 2025-2030
• 8.5 Adenocarcinoma - Market size and forecast 2025-2030
• 8.6 Others - Market size and forecast 2025-2030
• 8.7 Market opportunity by Disease Type
  • Market opportunity by Disease Type ($ million)

9 Market Segmentation by Drug Class

• 9.1 Market segments
• 9.2 Comparison by Drug Class
• 9.3 Immunotherapy drugs - Market size and forecast 2025-2030
• 9.4 Chemotherapy drugs - Market size and forecast 2025-2030
• 9.5 Target therapy drugs - Market size and forecast 2025-2030
• 9.6 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

10 Market Segmentation by End-user

• 10.1 Market segments
• 10.2 Comparison by End-user
• 10.3 Hospitals - Market size and forecast 2025-2030
• 10.4 Specialty clinics - Market size and forecast 2025-2030
• 10.5 Others - Market size and forecast 2025-2030
• 10.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Colombia - Market size and forecast 2025-2030
  • 12.6.7 South Africa - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Growing burden of bladder cancer diagnosis across aging populations
  • Expanding adoption of immunotherapy and targeted treatment approaches
  • Increasing investment in oncology research and clinical development programs
• 13.2 Market challenges
  • Limited access to specialized diagnosis and treatment infrastructure
  • Resource intensive treatment and monitoring requirements
  • Complex regulatory and reimbursement environment
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Growing shift toward non invasive diagnostic and monitoring solutions
  • Growing shift toward bladder preservation treatment strategies
  • Expanding collaboration ecosystem across pharmaceutical, biotechnology, and academic organizations

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Adaptimmune Therapeutics plc
  • Adaptimmune Therapeutics plc - Overview
  • Adaptimmune Therapeutics plc - Product / Service
  • Adaptimmune Therapeutics plc - Key offerings
  • SWOT
• 15.5 Asieris Pharmaceuticals
  • Asieris Pharmaceuticals - Overview
  • Asieris Pharmaceuticals - Product / Service
  • Asieris Pharmaceuticals - Key offerings
  • SWOT
• 15.6 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 15.7 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.8 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.9 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key news
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 Ferring BV
  • Ferring BV - Overview
  • Ferring BV - Product / Service
  • Ferring BV - Key offerings
  • SWOT
• 15.12 Incyte Corp.
  • Incyte Corp. - Overview
  • Incyte Corp. - Product / Service
  • Incyte Corp. - Key news
  • Incyte Corp. - Key offerings
  • SWOT
• 15.13 Johnson and Johnson
  • Johnson and Johnson - Overview
  • Johnson and Johnson - Business segments
  • Johnson and Johnson - Key news
  • Johnson and Johnson - Key offerings
  • Johnson and Johnson - Segment focus
  • SWOT
• 15.14 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.15 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.16 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.17 Photocure ASA
  • Photocure ASA - Overview
  • Photocure ASA - Product / Service
  • Photocure ASA - Key offerings
  • SWOT
• 15.18 UroGen Pharma Ltd
  • UroGen Pharma Ltd - Overview
  • UroGen Pharma Ltd - Product / Service
  • UroGen Pharma Ltd - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations